Question 1

Where is enGene's corporate headquarters located?

Accepted Answer

IMPORTANT TAX NOTICE TO U.S. SHAREHOLDERS This statement is provided for shareholders who are United States persons for purposes of the U.S. Internal Revenue Code of 1986, as amended (“IRC”) and the regulations thereunder. It should generally not be relevant to other shareholders. enGene Holdings Inc, (the “Company”) may be deemed to be classified as a Passive Foreign Investment Corporation (“PFIC”) as defined in section 1297 of the IRC during 2025, and may be deemed to have been a PFIC for prior years. TO ENSURE COMPLIANCE WITH TREASURY DEPARTMENT CIRCULAR 230, YOU ARE HEREBY NOTIFIED THAT ANYTHING CONTAINED IN THIS NOTICE CONCERNING ANY FEDERAL TAX OR OTHER ISSUE IS NOT INTENDED OR WRITTEN TO BE USED, AND CANNOT BE USED, BY ANY PERSON OR ENTITY FOR THE PURPOSE OF: (i) AVOIDING PENALTIES THAT MAY BE IMPOSED ON ANY TAXPAYER, OR (ii) PROMOTING, MARKETING OR RECOMMENDING TO ANOTHER PARTY ANY MATTERS ADDRESSED HEREIN.

Question 2

How is enGene stock traded?

Accepted Answer

enGene is traded on the NASDAQ Global Select Market under the ticker symbol ENGN.

Question 3

When did enGene go public?

Accepted Answer

enGene began public trading on Nov. 1, 2023.

Question 4

What is the business combination that resulted in enGene Inc. becoming a wholly owned subsidiary of enGene Holdings Inc?

Accepted Answer

On October 31, 2023, enGene Inc. completed a business combination with Forbion European Acquisition Corp. whereby, through a series of transactions, enGene Inc. became a wholly owned subsidiary of enGene Holdings Inc., which is a new public company listed on NASDAQ. Shares held by shareholders of Forbion European Acquisition Corp. and enGene Inc. were exchanged for shares of enGene Holdings Inc. The business combination is described in detail in the enGene Holdings Inc. proxy statement and prospectus, a copy of which was filed with the U.S. Securities and Exchange Commission on October 2, 2023, and can be found here: https://engene.com/sec-filings/   Effective April 8, 2026, enGene Holdings Inc. was renamed enGene Therapeutics Inc. In his FAQs section, we continue to refer to enGene Holdings Inc.

Question 5

What happened to my enGene Inc. shares?

Accepted Answer

As part of the business combination, each enGene Inc. share was exchanged for 0.1804799669 shares of enGene Holdings Inc.

Question 6

How do I receive my enGene Holdings Inc. shares in exchange for my enGene Inc. shares?

Accepted Answer

enGene Holdings Inc.’s transfer agent, Continental Stock Transfer & Trust Company, has sent each registered shareholder of enGene Inc. a Letter of Transmittal that sets out the process to exchange enGene Inc. shares for enGene Holdings Inc. shares.

Question 7

How many shares of enGene Holdings Inc. will I receive in exchange for my enGene Inc. shares?

Accepted Answer

The number of enGene Holdings Inc. shares that you will receive in exchange for your enGene Inc. shares will be equal to the number of enGene Inc. shares that you held prior to the business combination multiplied by the exchange ratio, which is 0.1804799669, with the result rounded down to the nearest whole share.

Question 8

How many shares of enGene Inc. did I hold prior to the business combination?

Accepted Answer

enGene Holdings Inc.’s transfer agent, Continental Stock Transfer & Trust Company, has sent each registered shareholder of enGene Inc. a Letter of Transmittal that sets out the number of enGene Inc. shares held by the shareholder prior to the business combination. Please contact Continental Stock Transfer & Trust Company for further information.

Question 9

Why does the number of shares in my Letter of Transmittal not match my records?

Accepted Answer

If you were a shareholder of enGene Inc. prior to 2016, the number of enGene Inc. shares you owned was automatically reduced as the result of a reverse stock split effected by enGene Inc. in 2016. The reverse stock split was described in the management information circular dated April 15, 2016, which was sent to all shareholders, and approved by the shareholders of enGene Inc. at a meeting held on April 29, 2016. If you became a shareholder enGene Inc. after 2016 and the number of shares in your Letter of Transmittal does not match your records, please contact Continental Stock Transfer & Trust Company.

Question 10

How do I update my contact info (email, address, etc)?

Accepted Answer

Please contact the transfer agent: Continental Stock Transfer & Trust Company Continental Stock Transfer & Trust Company One State Street 30th Floor New York, New York, 10004 Phone: 800-509-5586 or 212-509-4000 Email: cstmail@continentalstock.com

Question 11

I have not received my Letter of Transmittal yet - what do I?

Accepted Answer

Please contact the transfer agent.

Question 12

When is enGene's fiscal year-end?

Accepted Answer

The Company’s fiscal year ends on October 31st.

Question 13

How can I purchase shares?

Accepted Answer

Shares can be purchased through a stockbroker of your choice. enGene does not have a direct stock purchase plan.

Question 14

Who are enGene's independent auditors?

Accepted Answer

enGene’s independent auditor is KPMG.

Question 15

What is the company's CUSIP number?

Accepted Answer

29286X101

Question 16

How can I view documents enGene has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?

Accepted Answer

Quarterly and annual reports, as well as other SEC filings, can be accessed in the SEC Filings section of our Investors webpage or directly from the SEC at www.sec.gov .

Question 17

Whom should I contact if I have future questions?

Accepted Answer

You can submit questions to enGene’s investor relations team at Investors@enGene.com .

Question 18

Where is enGene's corporate headquarters located?

Accepted Answer

IMPORTANT TAX NOTICE TO U.S. SHAREHOLDERS This statement is provided for shareholders who are United States persons for purposes of the U.S. Internal Revenue Code of 1986, as amended (“IRC”) and the regulations thereunder. It should generally not be relevant to other shareholders. enGene Holdings Inc, (the “Company”) may be deemed to be classified as a Passive Foreign Investment Corporation (“PFIC”) as defined in section 1297 of the IRC during 2025, and may be deemed to have been a PFIC for prior years. TO ENSURE COMPLIANCE WITH TREASURY DEPARTMENT CIRCULAR 230, YOU ARE HEREBY NOTIFIED THAT ANYTHING CONTAINED IN THIS NOTICE CONCERNING ANY FEDERAL TAX OR OTHER ISSUE IS NOT INTENDED OR WRITTEN TO BE USED, AND CANNOT BE USED, BY ANY PERSON OR ENTITY FOR THE PURPOSE OF: (i) AVOIDING PENALTIES THAT MAY BE IMPOSED ON ANY TAXPAYER, OR (ii) PROMOTING, MARKETING OR RECOMMENDING TO ANOTHER PARTY ANY MATTERS ADDRESSED HEREIN.

Question 19

How is enGene stock traded?

Accepted Answer

enGene is traded on the NASDAQ Global Select Market under the ticker symbol ENGN.

Question 20

When did enGene go public?

Accepted Answer

enGene began public trading on Nov. 1, 2023.

Question 21

What is the business combination that resulted in enGene Inc. becoming a wholly owned subsidiary of enGene Holdings Inc?

Accepted Answer

On October 31, 2023, enGene Inc. completed a business combination with Forbion European Acquisition Corp. whereby, through a series of transactions, enGene Inc. became a wholly owned subsidiary of enGene Holdings Inc., which is a new public company listed on NASDAQ. Shares held by shareholders of Forbion European Acquisition Corp. and enGene Inc. were exchanged for shares of enGene Holdings Inc. The business combination is described in detail in the enGene Holdings Inc. proxy statement and prospectus, a copy of which was filed with the U.S. Securities and Exchange Commission on October 2, 2023, and can be found here . Effective April 8, 2026, enGene Holdings Inc. was renamed enGene Therapeutics Inc. In his FAQs section, we continue to refer to enGene Holdings Inc.

Question 22

What happened to my enGene Inc. shares?

Accepted Answer

As part of the business combination, each enGene Inc. share was exchanged for 0.1804799669 shares of enGene Holdings Inc.

Question 23

How do I receive my enGene Holdings Inc. shares in exchange for my enGene Inc. shares?

Accepted Answer

enGene Holdings Inc.’s transfer agent, Continental Stock Transfer & Trust Company, has sent each registered shareholder of enGene Inc. a Letter of Transmittal that sets out the process to exchange enGene Inc. shares for enGene Holdings Inc. shares.

Question 24

How many shares of enGene Holdings Inc. will I receive in exchange for my enGene Inc. shares?

Accepted Answer

The number of enGene Holdings Inc. shares that you will receive in exchange for your enGene Inc. shares will be equal to the number of enGene Inc. shares that you held prior to the business combination multiplied by the exchange ratio, which is 0.1804799669, with the result rounded down to the nearest whole share.

Question 25

How many shares of enGene Inc. did I hold prior to the business combination?

Accepted Answer

enGene Holdings Inc.’s transfer agent, Continental Stock Transfer & Trust Company, has sent each registered shareholder of enGene Inc. a Letter of Transmittal that sets out the number of enGene Inc. shares held by the shareholder prior to the business combination. Please contact Continental Stock Transfer & Trust Company for further information.

Question 26

Why does the number of shares in my Letter of Transmittal not match my records?

Accepted Answer

If you were a shareholder of enGene Inc. prior to 2016, the number of enGene Inc. shares you owned was automatically reduced as the result of a reverse stock split effected by enGene Inc. in 2016. The reverse stock split was described in the management information circular dated April 15, 2016, which was sent to all shareholders, and approved by the shareholders of enGene Inc. at a meeting held on April 29, 2016. If you became a shareholder enGene Inc. after 2016 and the number of shares in your Letter of Transmittal does not match your records, please contact Continental Stock Transfer & Trust Company.

Question 27

How do I update my contact info (email, address, etc)?

Accepted Answer

Please contact the transfer agent: Continental Stock Transfer & Trust Company Continental Stock Transfer & Trust Company One State Street 30th Floor New York, New York, 10004 Phone: 800-509-5586 or 212-509-4000 Email: cstmail@continentalstock.com

Question 28

I have not received my Letter of Transmittal yet - what do I?

Accepted Answer

Please contact the transfer agent.

Question 29

I have not received my Letter of Transmittal yet - what do I?

Accepted Answer

Please contact the transfer agent.

Question 30

When is enGene's fiscal year-end?

Accepted Answer

The Company’s fiscal year ends on October 31st.

Question 31

How can I purchase shares?

Accepted Answer

Shares can be purchased through a stockbroker of your choice. enGene does not have a direct stock purchase plan.

Question 32

Who are enGene's independent auditors?

Accepted Answer

enGene’s independent auditor is KPMG.

Question 33

What is the company's CUSIP number?

Accepted Answer

29286X101

Question 34

How can I view documents enGene has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?

Accepted Answer

Quarterly and annual reports, as well as other SEC filings, can be accessed in the SEC Filings section of our Investors webpage or directly from the SEC at www.sec.gov .

Question 35

Whom should I contact if I have future questions?

Accepted Answer

You can submit questions to enGene’s investor relations team at Investors@enGene.com .

Investor FAQs

Quick Links

Quick Links

Investor Email Alerts